Evidence map›Paper›PMID 32349790›Full record

ArticleAddiction science & clinical practice2020

Development of an integrated digital health intervention to promote engagement in and adherence to medication for opioid use disorder.

Kirsten J Langdon, Susan Ramsey, Caroline Scherzer, Kate Carey, Megan L Ranney, Josiah Rich

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Addiction science & clinical practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03842384 (iENDURE), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03842384 nacompletednot on this map

iENDURE: Digital Health Intervention to Support Opioid Use Disorder Treatment

TypeinterventionalSponsorRhode Island HospitalRan2020 to 2023Enrolled80ConditionsOpioid Use Disorder, Treatment AdherenceArmsiENDURE
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Misalignment of Stakeholder Incentives in the Opioid Crisis.International journal of environmental research and public health · 2020
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Kirsten J LangdonDepartment of Psychiatry, Rhode Island Hospital, 146 West River Street, Suite 11A, Providence, RI, 02904, USA. kirsten.langdon@lifespan.org.ORCID 0000-0001-8404-397X
Susan RamseyDepartment of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, USA.
Caroline ScherzerDepartment of Psychiatry, Rhode Island Hospital, 146 West River Street, Suite 11A, Providence, RI, 02904, USA.
Kate CareyDepartment of Behavioral and Social Sciences, Brown University School of Public Health, Providence, USA.
Megan L RanneyDepartment of Emergency Medicine, Alpert Medical School Brown University, Providence, USA.
Josiah RichDepartment of Medicine, Alpert Medical School of Brown University, Providence, USA.
Brown University · USProvidence College · US

Funding

Project 4: Neonatal Abstinence Syndrome (NAS): Fetus to First YearsP20GM125507 · NIGMS · RHODE ISLAND HOSPITAL · PI JOSIAH D RICH · 2018 to 2026
$23.4M
Integrated Digital Health Intervention to Promote Engagement in and Adherence to Medication-Assisted TreatmentK23DA046482 · NIDA · RHODE ISLAND HOSPITAL · PI LANGDON, KIRSTEN JOHNSON · 2019 to 2023
$911k
NIDA NIH HHS K23 DA046482NIDA NIH HHS K23DA046482NIGMS NIH HHS P20 GM125507NIGMS NIH HHS P20GM125507
6 · The paper itself

Abstract

backgroundBuprenorphine-naloxone is an evidence-based treatment for Opioid Use Disorder. However, despite its efficacy, nearly half of participants are unsuccessful in achieving stabilization (i.e., period of time following medication induction in which medication dose is adjusted to be effective in reducing cravings/withdrawal, minimize potential side effects, and eliminate illicit substance use). This paper presents the study design and protocol for a digital health intervention designed to promote engagement in and adherence to buprenorphine treatment, offered through an outpatient addiction treatment center, through motivational enhancement and distress tolerance skills training. Personalized feedback interventions represent a promising method to effectively motivate engagement in and adherence to buprenorphine treatment. These interventions are generally brief, individually tailored, and have the potential to be delivered via mobile platforms. Distress tolerance, a transdiagnostic vulnerability factor, has been implicated in the development and maintenance of substance use. Targeting distress tolerance may improve substance use treatment outcomes by promoting the ability to persist in goal-directed activity even when experiencing physical or emotional distress.

methodsThe study aims are to: (1) develop and refine an interactive computer- and text message-delivered personalized feedback intervention that incorporates distress tolerance skills training for persons who have elected to initiate outpatient buprenorphine treatment (iCOPE); (2) examine the feasibility, acceptability, and preliminary efficacy of iCOPE for increasing abstinence, adherence, and retention in treatment compared to a treatment as usual comparison condition; and, (3) examine potential mechanisms that may underlie the efficacy of iCOPE in improving outcomes, including motivation, distress tolerance, self-regulation, and negative affect. DISCUSSION: Results of this study will be used to determine whether to proceed with further testing through a large-scale trial. This work has the potential to improve treatment outcomes by reducing illicit opioid use, increasing adherence/retention, and preventing future overdose and other complications of illicit opioid use. Trial Registration NCT03842384.

Indexed as

FeedbackText MessagingAdultAgedBuprenorphineFemaleHumansMaleMedication AdherenceMiddle AgedMotivationNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersOutpatientsSubstance Abuse Treatment CentersBuprenorphineNarcotic AntagonistsBuprenorphineDistress toleranceMedications for opioid use disorderMobile treatmentMotivational enhancementOpioid use disorder

Identifiers

PMID32349790
PMCPMC7191734
OpenAlexW3021705177

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.